Related Experiment Videos
[Molecular diagnosis in hematopoietic malignancy]
A Hoshino1, T Funato, T Sasaki
1Department of Clinical and Laboratory Medicine, Tohoku University School of Medicine, Sendai.
Rinsho Byori. the Japanese Journal of Clinical Pathology
|February 1, 1996
Summary
Molecular diagnosis aids in understanding leukemia and detecting minimal residual disease. Techniques like PCR and IgH gene probes improve non-Hodgkin
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Context:
- Molecular analysis is crucial for understanding leukemia pathogenesis and minimal residual disease detection.
- Application of molecular diagnostics in malignant lymphomas is explored.
- Conventional methods struggle to detect specific chromosomal translocations in some non-Hodgkin's lymphomas (NHL).
Purpose:
- To demonstrate the utility of molecular techniques, such as PCR, for detecting specific chromosomal translocations (t(14;18)) in follicular lymphomas.
- To establish the use of immunoglobulin heavy chain (IgH) gene probes as tumor-specific markers for B-cell lymphomas.
- To develop methods for detecting minimal residual disease in bone marrow and peripheral blood of NHL patients.
Summary:
- Polymerase Chain Reaction (PCR) successfully detected the t(14;18) translocation in follicular lymphomas, even in cases negative by conventional analysis.
- IgH gene sequencing and PCR-based amplification using clone-specific primers or probes enabled tumor-specific marker identification.
- These molecular approaches allow for sequential detection of minimal residual disease in non-Hodgkin's lymphomas.
Impact:
- Molecular diagnostics offer a more sensitive alternative for identifying specific translocations in lymphomas.
- The development of tumor-specific molecular markers facilitates precise diagnosis and monitoring of B-cell malignancies.
- Molecular techniques are vital for improving the diagnosis, staging, and clinical management of patients with non-Hodgkin's lymphomas.